Change Visitor Type



Oxford Capital exited its investment in Sirigen in August 2012. Sirigen was acquired by Becton, Dickinson and Company, a leading global medical technology company for $65 million.

Sirigen commercialised a novel application of conducting polymers in the medical diagnostics market. Sirigen’s technology adds “high sensitivity fluorescence” (HSF) to diagnostic techniques, as well as simplifying sample processing and instrumentation requirements. Generating sufficient signal from diagnostic tests, in order to be sure of an accurate diagnosis, is a key challenge for the diagnostic industry. By incorporating the light-harnessing power of the Sirigen polymers, the signal from the diagnostic is greatly increased.

  • Push Dr primed to assist GPs to switch to digital consultations to combat Covid-19

    Read more
  • Curve Review – Is it the best way to combine all your cards?

    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • Wrisk has been announced as a finalist in the Insurtech category at the UK Fintech Awards 2020

    Read more
  • Read an interview with Rahul Powar at RedSift on Democratizing Data & Harnessing it for Email Security

    Read more
  • Waymo acquires Latent Logic to accelerate progress towards safe, driveless vehicles

    Read more
  • 2 of Oxford Capital’s portfolio highlighted in Britain’s Top 100 fastest growing businesses

    Read more